Analysts Set COMPASS Pathways plc (NASDAQ:CMPS) PT at $33.60

COMPASS Pathways plc (NASDAQ:CMPSGet Free Report) has earned an average recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $33.60.

A number of equities research analysts recently weighed in on the stock. Maxim Group cut their price objective on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and set a $18.00 price target on shares of COMPASS Pathways in a research report on Wednesday. Finally, HC Wainwright decreased their price objective on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a report on Friday, November 1st.

Get Our Latest Stock Analysis on COMPASS Pathways

COMPASS Pathways Stock Performance

CMPS opened at $3.41 on Tuesday. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average is $4.36 and its 200-day moving average is $5.89. The stock has a market cap of $233.31 million, a PE ratio of -1.55 and a beta of 2.27. COMPASS Pathways has a twelve month low of $3.16 and a twelve month high of $12.75.

COMPASS Pathways (NASDAQ:CMPSGet Free Report) last announced its earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.04. During the same period in the prior year, the company posted ($0.67) EPS. On average, analysts predict that COMPASS Pathways will post -2.33 earnings per share for the current year.

Institutional Investors Weigh In On COMPASS Pathways

A number of institutional investors and hedge funds have recently bought and sold shares of CMPS. Hennion & Walsh Asset Management Inc. grew its stake in shares of COMPASS Pathways by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company’s stock worth $661,000 after purchasing an additional 26,787 shares during the last quarter. Green Alpha Advisors LLC boosted its holdings in COMPASS Pathways by 138.3% during the fourth quarter. Green Alpha Advisors LLC now owns 37,614 shares of the company’s stock worth $142,000 after buying an additional 21,833 shares in the last quarter. Franklin Resources Inc. grew its position in COMPASS Pathways by 4.4% in the third quarter. Franklin Resources Inc. now owns 295,785 shares of the company’s stock worth $1,810,000 after buying an additional 12,599 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of COMPASS Pathways by 160.3% in the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock valued at $266,000 after buying an additional 25,970 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of COMPASS Pathways during the third quarter worth $131,000. 46.19% of the stock is owned by institutional investors and hedge funds.

About COMPASS Pathways

(Get Free Report

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

Read More

Analyst Recommendations for COMPASS Pathways (NASDAQ:CMPS)

Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.